Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report (CROSBI ID 306689)
Prilog u časopisu | Pismo uredniku | međunarodna recenzija
Podaci o odgovornosti
Sabljić, Zoran ; Bašić‐Jukić, Nikolina
engleski
Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report
We present a case of a 63‐year‐old female who developed toxic myopathy and liver damage after SARS‐CoV‐2 infection. She received her first renal transplant in 1989 for treatment of chronic glomerulonephritis. Her allograft failed in 1996 and renal function was replaced with intermittent hemodialysis until the second transplantation, which was performed in January 2001. She was treated with triple immunosuppressive therapy— tacrolimus, mycophenolate mofetil, and steroids. Also, in chronic therapy, she had atorvastatin 80 mg/day and ezetimibe 10 mg/day since April 2015, when she experienced myocardial infarction with implantation of stents in the coronary arteries. In April 2021, she was admitted to hospital due to SARS CoV‐2 infection with consequent pneumonia, which was treated with remdesivir, ceftriaxone, and dexamethasone, also with tacrolimus reduction and mycophenolate cessation. A few days after discharge from the hospital, she developed weakness of the proximal muscles of the arms and legs, which prevented her from getting up, walking, and leaning on her arms.
concomitant therapy ; myopathy ; SARS‐CoV‐2 ; pneumonia
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
26 (2)
2021.
478-479
objavljeno
1744-9979
10.1111/1744-9987.13748
Povezanost rada
Kliničke medicinske znanosti